Machine Learning to Reduce Hypertension Treatment Clinical Inertia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Gabriel Tajeu, DrPH
- Phone Number: 2055312258
- Email: gtajeu@uab.edu
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria: practicing primary care clinicians who see patients (i.e., internal medicine, family medicine, attending physicians, nurse practitioners) will be eligible to participate -
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: No Information from Machine Learning Algorithm
The investigators will create case vignettes to assess clinician hypertension management behavior, specifically antihypertensive medication intensification among individuals with uncontrolled blood pressure (BP).
This arm will not include information from a machine learning algorithm designed to predict uncontrolled BP at a follow up visit.
|
|
|
Experimental: Information from Machine Learning Algorithm
The investigators will create case vignettes to assess clinician hypertension management behavior, specifically antihypertensive medication intensification among individuals with uncontrolled blood pressure (BP).
This arm will include information from a machine learning algorithm designed to predict uncontrolled BP at a follow up visit about whether the algorithm predicts that the patient will have uncontrolled BP at the next visit.
|
The investigators have created a machine learning algorithm to predict uncontrolled blood pressure (BP) status (yes/no) at a follow up visit among adults with uncontrolled BP at their current visit.
The investigators will determine whether adding this information to a vignette describing a patient will increase the likelihood that a clinician will intensify antihypertensive medication treatment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Vignette #1 - antihypertensive medication treatment intensification
Time Frame: Immediately after clinical vignette
|
A clinical vignette of a patient with uncontrolled blood pressure will be presented to clinicians.
They will then be asked to assess wether they would intensify antihypertensive medication treatment.
This will be assessed using a 5-point Likert scale with scores ranging from 1 ("Strongly disagree") to 5 ("Strongly agree").
Likert scale scores will be compared between clinicians in the control and intervention group.
|
Immediately after clinical vignette
|
|
Vignette #2 - antihypertensive medication treatment intensification
Time Frame: Immediately after clinical vignette
|
A second clinical vignette of a patient with uncontrolled blood pressure will be presented to clinicians.
They will then be asked to assess wether they would intensify antihypertensive medication treatment.
This will be assessed using a 5-point Likert scale with scores ranging from 1 ("Strongly disagree") to 5 ("Strongly agree").
Likert scale scores will be compared between clinicians in the control and intervention group.
|
Immediately after clinical vignette
|
|
Vignette #3 - antihypertensive medication treatment intensification
Time Frame: Immediately after clinical vignette
|
A third clinical vignette of a patient with uncontrolled blood pressure will be presented to clinicians.
They will then be asked to assess wether they would intensify antihypertensive medication treatment.
This will be assessed using a 5-point Likert scale with scores ranging from 1 ("Strongly disagree") to 5 ("Strongly agree").
Likert scale scores will be compared between clinicians in the control and intervention group.
|
Immediately after clinical vignette
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gabriel Tajeu, DrPH, University of Alabama at Birmingham
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- K01HL151974 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.